Literature DB >> 177135

[Immunologic status in Hodgkin patients: correlation with Epstein-Barr virus titers].

V Diehl, K Hegge, J Kalden, U Desselberger, P Krull.   

Abstract

1. In Hodgkin's disease patient's immunological in vitro and in vivo parameters are of prognostic importance. 2. Skin test reactivity correlates to peripheral T-lymphocyte counts and Con A induced lymphoblastogenesis. 3. Con A is the most sensitive in vitro indicator for detecting latent immunodeficiency. 4. Hodgkin patients in long term remission after tumor reductive therapy exhibit a qualitative and quantitative lymphocyte defect. 5. In Hodgkin patients Herpes virus related antibody titers are elevated against Epstein Barr virus (EBV). The elevation coincides with a decreased T-cell number and function. Antibodies against other Herpes viruses (HSV, CMV, VZV) are in the normal range, when tested by the complement fixation method.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177135     DOI: 10.1007/bf01005310

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  9 in total

1.  Immune alterations in Hodgkin's disease. Effect of delayed hypersensitivity and lymphocyte transformation on course and survival.

Authors:  R C Young; M P Corder; C W Berard; V T DeVita
Journal:  Arch Intern Med       Date:  1973-03

2.  Antibody to Epstein-Barr virus and cellular immunity in Hodgkin's disease and chronic lymphatic leukemia.

Authors:  J Hesse; E Andersen; P H Levine; P Ebbesen; P Halberg; J I Reisher
Journal:  Int J Cancer       Date:  1973-01-15       Impact factor: 7.396

3.  Antibodies to Epstein-Barr virus, cytomegalovirus, and Australia antigen in Hodgkin's disease.

Authors:  M M Langenhuysen; T Cazemier; B Houwen; T M Brouwers; M R Halie; T H The; H O Nieweg
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

4.  Cellular immunity: immune responses and the herpes-like virus.

Authors:  P R Glade; K Hirschhorn
Journal:  Cell Immunol       Date:  1970-10       Impact factor: 4.868

5.  Lymphocyte response to phytohemagglutinin in Hodgkin's disease.

Authors:  T Han; J E Sokal
Journal:  Am J Med       Date:  1970-06       Impact factor: 4.965

6.  Impaired in vitro lymphocyte transformation in Hodgkin's disease.

Authors:  E M Hersh; J J Oppenheim
Journal:  N Engl J Med       Date:  1965-11-04       Impact factor: 91.245

7.  Intrinsic lymphocyte defect in Hodgkin's disease: analysis of the phytohemagglutinin dose-response.

Authors:  J B Ziegler; P Hansen; R Penny
Journal:  Clin Immunol Immunopathol       Date:  1975-03

8.  Impaired lymphocyte function in untreated Hodgkin's disease.

Authors:  R Levy; H S Kaplan
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

9.  Lymphoid cells in Hodgkin's disease.

Authors:  D Crowther; G H Fairley; R L Sewell
Journal:  Nature       Date:  1967-09-02       Impact factor: 49.962

  9 in total
  2 in total

1.  Persisting lymphocyte deficiences during remission in Hodgkin's disease.

Authors:  M Björkholm; G Holm; H Mellstedt
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

2.  [Hodgkin's disease: effect of spenectomy on the immune status (author's transl)].

Authors:  V Diehl; M Schaadt; R J Kalden; C Hagedorn; N Schmidt; J Deinhardt
Journal:  Klin Wochenschr       Date:  1978-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.